Women Reap the Benefits of Improvements in Coronary Stents

In a meta-analysis of patient-level data, the superiority of newer-generation drug-eluting stents in women was consistent with results of clinical trials in both sexes.

Randomized trials have demonstrated the overall safety and efficacy of drug-eluting stents in the treatment of coronary artery disease; however, approximately three quarters of trial participants have been men. Because no individual trial has been sufficiently powered to assess the safety and efficacy of drug-eluting stents in women, these investigators pooled patient-level data on 11,557 women (mean age, 67) enrolled in 26 drug-eluting–stent trials and analyzed outcomes according to stent type (bare-metal stents [BMS], early-generation drug-eluting stents, and newer-generation drug-eluting stents).

The distribution of assigned participants and outcomes in the three stent groups are shown in . Compared with both BMS and early-genera…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

Women Reap the Benefits of Improvements in Coronary Stents

Topics

Reviewing Author